Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Myasthenia Gravis × satralizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 6 zilucoplan 5 efgartigimod alfa 5 eculizumab 4 telitacicept 3 Tacrolimus 3 Amifampridine 3 ravulizumab 2 Rituximab 2 Prednisone 2 HBM9161 2 satralizumab 1 remibrutinib 1 iptacopan 1 inebilizumab 1 Thymectomy 1 Sugars 1 Steroids 1 Sodium Chloride 1 Pyridostigmine Bromide 1 Prednisolone 1 Mycophenolic Acid 1 Leflunomide 1 Hizentra 1 Cladribine 1 Azathioprine 1 Alkalies 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04963270 2025-02-28

A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis

Hoffmann-La Roche

Phase 3 Terminated

188 enrolled 40 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡